|
Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of $5.00 per American depository share, representing a 20% premium over the $4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially ‘transformative’ FLT201 programme to treat Gaucher disease. Current stock price: 126.30 pence, up 0.2% in London on Wednesday around noon 12-month change: down 24% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
